Erschienen in:
04.01.2021 | Letter to Editor
Benralizumab in Severe and Refractory PDGFRA-Negative Hypereosinophilic Syndrome
verfasst von:
Iolanda Alen Coutinho, Frederico S. Regateiro, Carlos Loureiro, Ana Todo-Bom
Erschienen in:
Journal of Clinical Immunology
|
Ausgabe 3/2021
Einloggen, um Zugang zu erhalten
Excerpt
Hypereosinophilic syndrome (HES) is a rare, heterogeneous group of disorders characterized by persistent, marked blood eosinophilia associated with eosinophil-induced tissue/organ damage, causing a wide range of clinical manifestations [
1]. Treatment includes glucocorticoids, immunosuppressors, and cytotoxic agents [
1]. A highly variable response to treatment reflects the heterogeneity of the syndrome, and some patients are resistant to glucocorticoid treatment [
1]. …